A - UBS lowers Agilent to neutral cites overexposure to Chinese market
2023-11-17 12:26:02 ET
More on Agilent Technologies
- Agilent Technologies: Looking Undervalued Heading Into Earnings
- Agilent Not As Agile As Hoped As Life Sciences Demand Proves To Be Less Than Invincible
- Agilent: Dips Into GARP Territory, Shares At A Crucial Spot On The Chart
- Agilent gastric cancer assay wins FDA nod
- Agilent Technologies declares $0.225 dividend
For further details see:
UBS lowers Agilent to neutral, cites overexposure to Chinese market